PIK3CA E545K
|
CRC
|
PIK3CA E545K
|
CRC
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
PIK3CA E545K
|
NSCLC
|
PIK3CA E545K
|
NSCLC
|
osimertinib Resistant: C3 – Early Trials
|
osimertinib Resistant: C3 – Early Trials
|
PIK3CA E545K
|
Ovarian Cancer
|
PIK3CA E545K
|
Ovarian Cancer
|
TAS-117 Sensitive: C3 – Early Trials
|
TAS-117 Sensitive: C3 – Early Trials
|
PIK3CA E545K
|
Breast Cancer
|
PIK3CA E545K
|
Breast Cancer
|
olaparib + durvalumab + AZD5363 Sensitive: C3 – Early Trials
|
olaparib + durvalumab + AZD5363 Sensitive: C3 – Early Trials
|
PIK3CA E545K
|
Gastric Cancer
|
PIK3CA E545K
|
Gastric Cancer
|
CYH33 Sensitive: C4 – Case Studies
|
CYH33 Sensitive: C4 – Case Studies
|
PIK3CA E545K
|
Breast Cancer
|
PIK3CA E545K
|
Breast Cancer
|
CYH33 Sensitive: C4 – Case Studies
|
CYH33 Sensitive: C4 – Case Studies
|
PIK3CA E545K
|
Ovarian Cancer
|
PIK3CA E545K
|
Ovarian Cancer
|
CYH33 Sensitive: C4 – Case Studies
|
CYH33 Sensitive: C4 – Case Studies
|
PIK3CA E545K
|
Breast Cancer
|
PIK3CA E545K
|
Breast Cancer
|
GDC-0941 Sensitive: D – Preclinical
|
GDC-0941 Sensitive: D – Preclinical
|
PIK3CA E545K
|
Breast Cancer
|
PIK3CA E545K
|
Breast Cancer
|
MK-2206 Sensitive: D – Preclinical
|
MK-2206 Sensitive: D – Preclinical
|
PIK3CA E545K
|
Breast Cancer
|
PIK3CA E545K
|
Breast Cancer
|
lapatinib Sensitive: D – Preclinical
|
lapatinib Sensitive: D – Preclinical
|
PIK3CA E545K
|
HER2 Positive Breast Cancer
|
PIK3CA E545K
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: D – Preclinical
|
ado-trastuzumab emtansine Sensitive: D – Preclinical
|
PIK3CA E545K
|
Breast Cancer
|
PIK3CA E545K
|
Breast Cancer
|
trastuzumab + lapatinib Resistant: D – Preclinical
|
trastuzumab + lapatinib Resistant: D – Preclinical
|
PIK3CA E545K
|
Thyroid Gland Papillary Carcinoma
|
PIK3CA E545K
|
Thyroid Gland Papillary Carcinoma
|
MK-2206 Sensitive: D – Preclinical
|
MK-2206 Sensitive: D – Preclinical
|
PIK3CA E545K
|
SCCHN
|
PIK3CA E545K
|
SCCHN
|
RTB101 Sensitive: D – Preclinical
|
RTB101 Sensitive: D – Preclinical
|
PIK3CA E545K
|
SCCHN
|
PIK3CA E545K
|
SCCHN
|
BMS-722782 Resistant: D – Preclinical
|
BMS-722782 Resistant: D – Preclinical
|
PIK3CA E545K
|
SCCHN
|
PIK3CA E545K
|
SCCHN
|
trametinib Resistant: D – Preclinical
|
trametinib Resistant: D – Preclinical
|
PIK3CA E545K
|
SCCHN
|
PIK3CA E545K
|
SCCHN
|
GDC-0941 Resistant: D – Preclinical
|
GDC-0941 Resistant: D – Preclinical
|
PIK3CA E545K
|
SCCHN
|
PIK3CA E545K
|
SCCHN
|
rigosertib Sensitive: D – Preclinical
|
rigosertib Sensitive: D – Preclinical
|
PIK3CA E545K
|
SCCHN
|
PIK3CA E545K
|
SCCHN
|
GDC-0032 Sensitive: D – Preclinical
|
GDC-0032 Sensitive: D – Preclinical
|
PIK3CA E545K
|
Melanoma
|
PIK3CA E545K
|
Melanoma
|
vemurafenib Resistant: D – Preclinical
|
vemurafenib Resistant: D – Preclinical
|
PIK3CA E545K
|
HCC
|
PIK3CA E545K
|
HCC
|
alpelisib Sensitive: D – Preclinical
|
alpelisib Sensitive: D – Preclinical
|
PIK3CA E545K
|
Hormone Receptor Positive Breast Cancer
|
PIK3CA E545K
|
Hormone Receptor Positive Breast Cancer
|
abemaciclib + RLY-2608 Sensitive: D – Preclinical
|
abemaciclib + RLY-2608 Sensitive: D – Preclinical
|
PIK3CA E545K
|
Hormone Receptor Positive Breast Cancer
|
PIK3CA E545K
|
Hormone Receptor Positive Breast Cancer
|
palbociclib + RLY-2608 Sensitive: D – Preclinical
|
palbociclib + RLY-2608 Sensitive: D – Preclinical
|
PIK3CA E545K
|
Hormone Receptor Positive Breast Cancer
|
PIK3CA E545K
|
Hormone Receptor Positive Breast Cancer
|
RLY-2608 Resistant: D – Preclinical
|
RLY-2608 Resistant: D – Preclinical
|